Mechanism of Action of Latanoprostene Bunod
Latanoprostene bunod lowers intraocular pressure through a dual mechanism: it is rapidly metabolized in the eye to latanoprost acid (a prostaglandin F2α analog) and butanediol mononitrate (a nitric oxide-donating moiety), which work synergistically to enhance aqueous humor outflow through both the uveoscleral pathway and the trabecular meshwork/Schlemm's canal pathway. 1
Metabolic Conversion and Active Components
After topical ocular administration, latanoprostene bunod undergoes rapid enzymatic hydrolysis in the eye, yielding two pharmacologically active metabolites 1:
- Latanoprost acid: An F2α prostaglandin analog that acts on prostaglandin F receptors
- Butanediol mononitrate (BDMN): A nitric oxide-releasing moiety that subsequently releases NO
This metabolic conversion occurs so rapidly that latanoprostene bunod itself is not detectable in plasma (below the lower limit of quantitation of 10.0 pg/mL), and butanediol mononitrate is similarly undetectable systemically (LLOQ 200 pg/mL) 1.
Dual Pathway Enhancement of Aqueous Outflow
Uveoscleral Pathway (Latanoprost Acid Component)
The latanoprost acid metabolite increases aqueous humor drainage through the uveoscleral (unconventional) outflow pathway by remodeling extracellular matrix in the ciliary muscle bundles, facilitating fluid movement through the ciliary body into the suprachoroidal space 2, 1, 3.
Trabecular Meshwork Pathway (Nitric Oxide Component)
The nitric oxide released from BDMN enhances aqueous outflow through the conventional trabecular meshwork/Schlemm's canal pathway via multiple mechanisms 3:
- Increases cyclic GMP levels in trabecular meshwork cells and aqueous humor
- Reduces myosin light chain phosphorylation, leading to trabecular meshwork cell relaxation
- Induces cytoskeletal rearrangement in trabecular meshwork cells
- Decreases resistance to aqueous humor flow through the conventional outflow pathway
Nonclinical studies demonstrated that latanoprostene bunod reduced resistance to current flow and induced greater trabecular meshwork cell relaxation compared to latanoprost alone, confirming the additional contribution of the NO component 3.
Evidence of Dual Mechanism Superiority
The dual mechanism provides enhanced IOP reduction beyond latanoprost monotherapy. In FP receptor knockout mice (which lack functional prostaglandin receptors), latanoprostene bunod still lowered IOP more effectively than latanoprost, demonstrating that the NO component functions independently of the prostaglandin pathway 3. This was further confirmed in multiple animal models including rabbits with transient ocular hypertension, glaucomatous dogs, and primates with ocular hypertension 3.
Clinical Pharmacodynamics
IOP reduction begins approximately 1-3 hours after administration, with maximum effect at 11-13 hours in eyes with elevated intraocular pressure 1. The latanoprost acid component reaches peak plasma concentration (Tmax) at approximately 5 minutes post-administration and is rapidly eliminated, with plasma concentrations dropping below quantifiable levels within 15 minutes in most subjects 1.
Additional Metabolic Pathways
After reaching systemic circulation, latanoprost acid undergoes hepatic metabolism via fatty acid β-oxidation to 1,2-dinor and 1,2,3,4-tetranor metabolites. The butanediol mononitrate is metabolized to 1,4-butanediol and nitric oxide; 1,4-butanediol is further oxidized to succinic acid and enters the tricarboxylic acid (TCA) cycle 1.
Clinical Significance
This dual mechanism addresses both major aqueous outflow pathways simultaneously, which is particularly relevant since the trabecular meshwork pathway accounts for approximately 75-90% of aqueous drainage in healthy eyes but becomes increasingly dysfunctional in glaucoma. The addition of NO-mediated trabecular outflow enhancement to prostaglandin-mediated uveoscleral outflow provides complementary IOP reduction 2, 4, 5.